FAM215A

Across TCGA pan-cancer cohorts, FAM215A RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated FAM215A data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher FAM215A RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated FAM215A expression acts as an unfavorable survival marker, although some lineages such as CHOL and LUAD show a favorable association.

CHOL, LUAD, and LAML are the cancer types where FAM215A RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Tertile	All	0.830	0.248	.001	57	view →
LUAD	DFS	Median	All	0.741	0.594	<.001	57	view →
LAML	DFS	Median	All	0.431	0.708	<.001	40	view →
UCEC	OS	Median	IV	0.652	0.229	<.001	36	view →
READ	OS	Quartile	II,III,IV	0.686	0.956	.006	27	view →
LIHC	OS	Tertile	II,III,IV	0.431	0.668	.002	27	view →
CESC	OS	Tertile	IV	0.855	0.407	.016	20	view →
BLCA	DFS	Quartile	III,IV	0.674	0.414	.014	19	view →
COAD	OS	Tertile	IV	0.385	0.724	.010	18	view →
ACC	DFS	Tertile	IV	0.065	0.373	.035	15	view →
HNSC	DFS	Tertile	All	0.774	0.663	.011	12	view →
MESO	DFS	Median	IV	0.477	0.209	.030	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

FAM215A–CHOL (DFS)

Open the CHOL breakdown →